How has it been working in the MIT Portugal Program?
CLS: Being part of MIT Portugal has been one of the best things that could have happened to me. Even at a very early stage in my career, I’ve had the chance to work with people like [MIT Institute Professor] Bob Langer and [Associate Professor] Sangeeta Bhatia. Without the MIT Portugal connection, I never would have had such an opportunity. It has been a very important step in my career. JJ: While part of the MIT Portugal Bioengineering group, you have been involved in direct partnerships with the Portuguese Oncology Institute (IPO) Francisco Gentil, in Lisbon. Can you say what’s important to you about working directly with clinical facilities? CLS: Our lab’s work with IPO focused on developing a strategy for the treatment and prevention of immunological complications after a bone marrow transplant, the common clinical practice to treat leukemia. In general, I am interested in working with clinicians and hospitals in order to have physicians recognize our research, and to know they can
